These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 12439841)

  • 1. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].
    Vallero A; Cesano G; Pozzato M; Garbo R; Minelli M; Quarello F; Formica M
    G Ital Nefrol; 2002; 19(5):529-33. PubMed ID: 12439841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
    Boccalandro F; Amhad M; Smalling RW; Sdringola S
    Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
    Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
    Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine.
    Briguori C; Colombo A; Airoldi F; Morici N; Sangiorgi GM; Violante A; Focaccio A; Montorfano M; Carlino M; Condorelli G; Ricciardelli B
    Kidney Int; 2005 Nov; 68(5):2250-5. PubMed ID: 16221226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?
    Kefer JM; Hanet CE; Boitte S; Wilmotte L; De Kock M
    Acta Cardiol; 2003 Dec; 58(6):555-60. PubMed ID: 14713182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of contrast agent-induced renal impairment in patients with chronic renal insufficiency and heart disease by high-dose intravenous N-acetylcysteine: a pilot-ministudy.
    Sochman J; Krizova B
    Kardiol Pol; 2006 Jun; 64(6):559-64; discussion 565-6. PubMed ID: 16810570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
    Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
    J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
    Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.
    Seyon RA; Jensen LA; Ferguson IA; Williams RG
    Heart Lung; 2007; 36(3):195-204. PubMed ID: 17509426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
    Alessandri N; Lanzi L; Garante CM; Tersigni F; Sergiacomi R; Petrassi M; Di Matteo A; Tufano F
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():13-21. PubMed ID: 23436661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures--a randomised controlled trial.
    Kotlyar E; Keogh AM; Thavapalachandran S; Allada CS; Sharp J; Dias L; Muller D
    Heart Lung Circ; 2005 Dec; 14(4):245-51. PubMed ID: 16360994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial.
    Fung JW; Szeto CC; Chan WW; Kum LC; Chan AK; Wong JT; Wu EB; Yip GW; Chan JY; Yu CM; Woo KS; Sanderson JE
    Am J Kidney Dis; 2004 May; 43(5):801-8. PubMed ID: 15112170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.
    Briguori C; Airoldi F; D'Andrea D; Bonizzoni E; Morici N; Focaccio A; Michev I; Montorfano M; Carlino M; Cosgrave J; Ricciardelli B; Colombo A
    Circulation; 2007 Mar; 115(10):1211-7. PubMed ID: 17309916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?
    Heng AE; Cellarier E; Aublet-Cuvelier B; Decalf V; Motreff P; Marcaggi X; Deteix P; Souweine B
    Clin Nephrol; 2008 Dec; 70(6):475-84. PubMed ID: 19049703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in low-risk populations undergoing coronary artery angiography.
    Calabrò P; Bianchi R; Crisci M; Caprile M; Bigazzi MC; Palmieri R; Golia E; De Vita A; Romano IJ; Limongelli G; Russo MG; Calabrò R
    Intern Emerg Med; 2011 Dec; 6(6):503-7. PubMed ID: 21279477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design.
    Briguori C; Visconti G; Ricciardelli B; Condorelli G;
    EuroIntervention; 2011 Apr; 6(9):1117-22, 7. PubMed ID: 21518686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.